Polyethylene glycol interferon-alpha2b alone or in combination with low-dose Ara-C in patients newly diagnosed with chronic myeloid leukemia

Haematologica. 2004 Jul;89(7):870-1.

Abstract

Thirty-five patients newly diagnosed with chronic myeloid leukemia received pegylated interferon alpha-2b (PEG-IFN) alone or combined with intermittent Ara-C for a median of 6.5 months (range: 1.4-19.2). The median weekly PEG-IFN dose was 4.0 microg/kg. Complete hematologic, major and complete cytogenetic responses were observed in 73%, 32% and 14%, respectively. Extra-hematologic side-effects were frequent and 20% of patients had grade III-IV hematologic toxicity.

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Antimetabolites, Antineoplastic / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cytarabine / administration & dosage*
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Male
  • Middle Aged
  • Polyethylene Glycols / administration & dosage*
  • Recombinant Proteins

Substances

  • Antimetabolites, Antineoplastic
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Cytarabine
  • Polyethylene Glycols
  • peginterferon alfa-2a